Year in Review: New Guidelines, Inclisiran, Dapagliflozin Impact CVD Prevention in 2019
Headlines have led to outside-the-box thinking as well as a more global perspective in preventing CV disease and events.
Related Articles
Should We Be Looking for ‘Occlusion MI’ Rather Than STEMI?
STEMI criteria alone aren’t perfect for identifying occluded arteries, but still some question the need for a new paradigm.
COVID-19: TCTMD’s Daily Dispatch (Long Version)
We’re curating a list of COVID-19 research and other useful content, and updating it daily.
Fellows 2025
Sign Up for Our Newsletter Get the latest news and updates from TCTMD. Forgot Your Password? Enter the email you used to register to reset…
Fellows 2025
Sign Up for Our Newsletter Get the latest news and updates from TCTMD. Forgot Your Password? Enter the email you used to register to reset…
Fellows 2025
Sign Up for Our Newsletter Get the latest news and updates from TCTMD. Forgot Your Password? Enter the email you used to register to reset…
Apixaban Bests Rivaroxaban, Warfarin in Preventing VTE Recurrence and Bleeding
The advantage of apixaban was consistent across a variety of subgroups and confirms earlier observations.
Higher CVD Risk in Children as Young as 10 Who Have Central Adiposity
At this early age, metabolism is already dysregulated and lifestyle changes are warranted to prevent future disease.
Procedural MIs Have Little Effect on Quality of Life: ISCHEMIA
Trialists should focus less on physician-defined outcomes and more on what matters to patients, Mario Gaudino says.
Actioning the Data: Earlier AS Referral in the Real World
Bernard Prendergast and Jordan Strom discuss the evolution of AS referral and how earlier treatment impacts patient outcomes.
The EARLY TAVR Trial: Best Practices for Referrer and Patient Engagement
Philippe Généreux, Brad Oldemeyer, and Jennifer Daniel share their experiences treating asymptomatic aortic stenosis patients in the EARLY TAVR trial.